However, in the current issue of the Journal of Human Hypertension we publish a paper by Onder and colleagues 4 documenting the rate of decline in the use of thiazide diuretics in Italy. There is every reason to believe that trends are similar elsewhere. Why is this? Why are we still opting to use expensive drugs, some of which have not yet been validated in long-term outcome studies, when the evidence is that the cheapest and longest established drugs are probably the best?
Prescribing habits amongst clinicians are rarely 'evidence-based'. The authoritative guidelines that exist recommend diuretic therapy as first-line treatment for hypertension, but offer other choices, and these guidelines may anyway not be widely adhered to. [5] [6] [7] One reason for this is ambivalence and inconsistency in the guidelines. Onder and co-workers drew attention to this point in the article. 4 Prescribing behaviour is often related to the enthusiasm of the latest speaker at a postgraduate meeting or to good feelings about a particular drug company or its representatives or even the quality of the free lunch. In the field of hypertension where there is such a wide choice of drugs, clinicians are subjected to a great many influences. There are few commercial advantages in promoting the thiazides, since profit margins are likely to be small. By contrast, the huge costs of the development of modern drugs mean that drug companies are naturally keen to recoup their investment in the newer agents such as the ACEinhibitors and the angiotensin antagonists. The lack of marketing is one reason why the thiazides are underused.
Another reason for the underuse of the thiazide diuretics is that there are theoretical reasons to believe that the beta-blockers and the ACE inhibitors might have advantages, even though such advantages have not been shown in long-term outcome trials. Many of us hoped that the beta-blockers would be 'cardioprotective' although the MRC trial and several other studies showed that they were not. 8, 9 Many now believe that the ACE-inhibitors are attractive with their properties of reducing left ventricular hypertrophy, improving heart failure, and left ventricular systolic dysfunction, as well as delaying renal impairment due to diabetic and nondiabetic nephropathy. [10] [11] [12] [13] Both the HOPE and MICRO-HOPE studies also provide evidence of the benefits of ACE inhibitors although it remains uncertain whether the better outcome was due to the better blood pressure control rather than any special efforts of ACE inhibitors. 14, 15 However, the 'old' antihypertensive agents (including hydrochlorothiazide 25 mg plus amiloride 2.5 mg daily) and newer agents including two ACE inhibitors, were equally effective in preventing fatal and non-fatal end-points in the STOP-H2 study, and the HANE study failed to find any advantage for ACE inhibitors or calcium antagonists over hydrochlorothiazide. 9, 16 Similarly, in the recent INSIGHT trial, calcium blockers were no better than thiazide diuretics at preventing heart attacks or strokes. 17 We will have to wait for a few years before we know whether the advantages of ACE-inhibitors in essential hypertension are anything more than theoretical. The publication of the ALLHAT and ASCOT studies will be important events. 18, 19 Another consideration is the spectre of the well known metabolic adverse effects of the thiazide diuretics. It is true that in high dose these drugs do have adverse effects on glucose metabolism, plasma lipids, and serum potassium and uric acid concentrations, as well as the haematocrit. Every medical student can reel off these horrors.
It is amazing that we had to wait until 1991 until we found out what the correct dose of bendrofluazide was! 20 Many of us, in the past, were prescribing thiazides in enormous doses; it comes as a shock to remember that in the MRC trial of treatment of mild hypertension in the non-elderly the dose of bendrofluazide was 5 mg twice daily! 8 We now know that, using the correct dose, the biochemical adverse effects of thiazide diuretics are very minor.
Perhaps the biggest concern has been about use of thiazide diuretics in patients with diabetes mellitus. Our students are told it is almost malpractice to give thiazide diuretics to diabetics patients because they may worsen glucose intolerance, although in fact this effect is trivial when the drugs are used in low dose. However, glucose intolerance is strongly correlated with the severity of hypokalaemia, and the adverse effects are reversible on stopping treatment. 21 The effects are anyway probably irrelevant in patients treated with insulin. 22 The serious consequences of hypertension in patients with Type 2 diabetes, where deaths related to diabetes are reduced by 19% for every 10 mm Hg reduction in systolic blood pressure, argue strongly for effective blood pressure treatment in all diabetic patients. 23 Furthermore, sub-group analysis of the use of thiazide diuretics in the SHEP study showed that diabetic patients derived as much benefit from their thiazides as non-diabetic patients and possibly even slightly more. 24 Thiazide diuretics can increase serum uric acid concentrations, but this may or may not matter. The question of whether hyperuricaemia is an independent risk factor has been raised again recently with the demonstration that losartan can reduce serum uric acid concentrations. 25 The epidemiological evidence up to now suggests that uric acid concentration is of little importance. 26 The effect of thiazide diuretics on serum cholesterol concentration is tiny compared with the benefits, in terms of cardiovascular prevention, of lowering the blood pressure. 20 The crux, of course, is that the outcome studies show the overall benefits of using thiazide diuretics.
The fall of serum potassium concentration with thiazide diuretics is usually trivial but all medical students know that thiazide diuretics are a 'cause' of hypokalaemia. In fact this is rarely the case, and if a patient, receiving a thiazide diuretic in a sensible dose, develops frank hypokalaemia, then another cause should be sought. Maybe the patient has aldosterone excess or, if Northern European, is consuming too much salted liquorice.
The adverse effects of the thiazide diuretics on male (and female) sexual function are probably better documented and many clinicians take the view that they are not the optimum drug to used as firstline therapy in sexually active men. However, an analysis of men (aged 45-65) in the TOHMS study showed a rather high incidence (14.9%) of erectile difficulties before treatment, which increased slightly with thiazide treatment, but which was not significantly different from placebo in any active treatment group after 48 months. 27 The recent INSIGHT study, comparing a modified release preparation of nifedipine with coamilozide (hydrochlorothiazide + amiloride) in over 2800 men recorded a similarly low incidence (1.5-2%) of impotence in both groups. 17 It is interesting that most drug companies and most clinicians are entirely happy to see a thiazide diuretic added in to their own choice of first-line drug. Thus, the optimum drug to add to a betablocker is a thiazide diuretic and similar recommendations are made with regard to the ACE-inhibitors. We now know that around 70% of hypertensive patients need more than one drug to control their blood pressure if a target of 140/80 mm Hg is to be achieved. 28 This means that a very large proportion of patients will end up having a thiazide diuretic added-in to their first-line drug. It would surely be more rational to use the thiazide as the first-line drug and add-in the beta-blocker or the ACE-inhibitor as a second-line agent if necessary.
All in all, there is every reason to restore thiazide diuretics to their place as first and best of the currently available hypertensive agents, particularly for older patients (ie, the majority) where they are more effective than beta-blockers at lowering blood pressure and preventing vascular complications. 29 
